Gruss Capital Management’s Repros Therapeutics Inc. RPRX Stock Holding History

Gruss Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-600,000	Closed	-$582K	–	66
2016 Q1	$582K	Buy	600,000 +296,000	+97%	+$289K	0.02%	52
2015 Q4	$368K	Hold	304,000	–	–	0.01%	80
2015 Q3	$2.26M	Hold	304,000	–	–	0.07%	67
2015 Q2	$2.17M	Hold	304,000	–	–	0.08%	62
2015 Q1	$2.61M	Buy	304,000 +28,000	+10%	+$250K	0.11%	56
2014 Q4	$2.75M	Buy	276,000 +26,000	+10%	+$222K	0.08%	68
2014 Q3	$2.48M	Buy	+250,000	New	+$3.7M	0.11%	50

Other funds holding RPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

AIA

Allegis Investment Advisors Idaho Falls, Idaho $326M AUM 10.36% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

BIM

Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return

Gruss Capital Management's RPRX Position: Q2 2016 in Review

Gruss Capital Management sold out of Repros Therapeutics Inc. (RPRX) in Q2 2016, closing a stake of 600,000 shares — an estimated $582K sold.

Gruss Capital Management first reported a position in RPRX in Q3 2014 and held it in 7 quarters. The position peaked at $2.75M in Q4 2014. 43 funds tracked by Wall St. Rank hold RPRX as of Q2 2016.

Gruss Capital Management reported no remaining Repros Therapeutics Inc. position as of Q2 2016 after selling out during the quarter.
Gruss Capital Management sold 600,000 Repros Therapeutics Inc. shares in Q2 2016, an estimated $582K.
Gruss Capital Management first reported a position in Repros Therapeutics Inc. in Q3 2014 and held it in 7 quarters.
Gruss Capital Management's Repros Therapeutics Inc. position peaked at $2.75M in Q4 2014.
43 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q2 2016.

Based on Gruss Capital Management's 13F filing for Q2 2016, filed 12 Aug 2016.